Characteristics | Overall | Metastatic | Locally Advanced |
Median Age | 53.00 ± 10.787 | 50.62 ± 10.02 | 54.97 ± 11.06 |
Chemo duration | 3 weekly | 3 weekly | 3 weekly |
Pre-menopausal | 20/65 | 11/26 | 9/39 |
Post-menopausal | 45/65 | 15/26 | 30/39 |
HER2 by IHC 3+ | 45/65 | 17/26 | 28/39 |
HER2 (IHC 2+) confirmed by FISH | 20/65 | 9/26 | 11/39 |
Hormonal status (ER, PR, HER2 neu) Triple Positive ER & PR negative, HER2 positive |
31/65 34/65 |
9/26 17/26 |
22/39 17/39 |
Chemotherapy regimen AC → Paclitaxel + Trastuzumab TCH |
30/65 35/65 |
15/26 13/26 |
25/39 22/39 |
Ki 67 > 20 Ki 67 < 20 | 64/65 1/65 | 26/26 1/26 | 38/39 0/39 |